BMS licenses SARS-CoV-2 neutralizing mAb combo

By The Science Advisory Board staff writers

February 3, 2021 -- Bristol Myers Squibb (BMS) has entered into an agreement with Rockefeller University to license a SARS-CoV-2 neutralizing monoclonal antibody (mAb) combination.

The mAbs have been engineered to be highly potent and stable, allowing them to last longer in the bloodstream. Preclinical data suggests that the combination of the two mAbs may be an effective treatment against multiple variants of the virus. The increased half-life of the product was enabled by leveraging Xencor's fragment crystallizable (Fc) engineering technology.

Phase I clinical trials to assess intravenous and subcutaneous formulations of the combination mAbs were initiated in mid-January.

BMS has been granted a global exclusive license to develop, manufacture, and commercialize Rockefeller's novel mAb combination treatment that neutralizes SARS-CoV-2 for the therapy or prevention of COVID-19. Under the agreement, Rockefeller University is eligible to receive royalty payments on future sales.

OSE, MabSilico collaborate on AI-driven mAb development
OSE Immunotherapeutics and MabSilico have partnered to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody (mAb) drug...
Humanigen expands partnership with BARDA for COVID-19 mAb manufacturing
Humanigen has expanded its cooperative research and development agreement with the U.S. Department of Defense Joint Program Executive Office for Chemical,...
Regulatory Roundup: antibodies, immunotherapies, expanded flu treatment use
Welcome to this week's edition of Regulatory Roundup. This past week, several novel therapies for the treatment of rare diseases and cancers have received...
Caribou inks deal with MSK to make allogeneic therapies
Memorial Sloan Kettering Cancer Center (MSK) has agreed to exclusively license its antibody fragments to CRISPR genome editing firm Caribou Biosciences...

Copyright © 2021

Glasgow International Health Festival
January 25-26, 2023
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter